Patients with low pulmonary vascular resistance may benefit from complex procedure for PH

May 18, 2014

Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers.

The study was presented at the 2014 American Thoracic Society International Conference.

UCSD pioneered PTE in the 1970s for who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). During PTE, surgeons put a patient on a heart-lung machine, cool the body to reduce its need for oxygen and then turn the machine off for up to 20 minutes so they can remove clots and scar tissue from the patient's arteries. Because of the procedure's complexity, it has been used, until recently, only to help patients whose pulmonary thromboembolic disease causes severe hypertension and has not responded to other therapies.

"Over the past five years, an increasing number of patients with symptomatic chronic thromboembolic disease, without severe pulmonary hypertension, are being offered and choosing to undergo the surgery, said lead investigator Daniel Crouch, MD, a third-year pulmonary and critical care fellow at UCSD. "These patients have symptoms that create a major burden in their lives. However, given that they do not have severe pulmonary hypertension and cardiac dysfunction, the benefits of the surgery must greatly outweigh the risks. "

In a retrospective chart review of patients who underwent PTE at UCSD between July 2010 and June 2013, Crouch found that 64 subjects had pre-operative pulmonary resistance values (PVRs) less than 300 dyn∙/cm5 and 355 patients had PVRs above 300dyn∙/cm5. (The value is used at UCSD as a guide to identify patients with severe and non-severe .) In the UCSD study, both groups had similar mean age and gender composition, while the (32.57 vs 30.18) was higher in the low PVR group.

Crouch and his colleagues found that those in the low PVR group had lower mortality (0 vs. 1.1%) and fewer complications, including delirium (7.8% vs. 14.9%), pneumonia/tracheobronchitis (6.3% vs. 15.5%), and a statistically significant lower rate of reperfusion lung injury (7.8% vs. 25.9%), The low PVR group also experienced statistically significant recoveries, with less time spent on the ventilator (1.7 vs. 3.2 days), in the ICU (4 vs. 5.8 days) and in the hospital (13 vs. 16.3 days).

Anecdotally, Crouch added, patients in the low PVR group showed "great benefit" in follow up visits. Nonetheless, the program is conducting a follow-up study to evaluate formally improvement in their functional status and quality of life. With higher (BMI) and a higher rate of simultaneous coronary artery bypass grafting (9.4% vs. 15.5%), he said, those in the low group may have other factors that contribute to their symptoms before surgery.

"Although pulmonary thromboendarterectomy is the procedure of choice for CTEPH, there are important questions to answer before it can be considered the treatment of choice in the low PVR patient population," Crouch said. "As with anything we offer patients, we want to prove it's the best therapy."

Explore further: First guidelines for patients with pulmonary hypertension in sickle cell disease

More information: Pulmonary Thromboendarterectomy In Patients With Chronic Pulmonary Thromboembolic Disease And Low Preoperative Pulmonary Vascular Resistance, Scientific Abstract , 18.08 - Pulmonary Embolism: Acute and Chronic (PC) , D.R. Crouch, P.F. Fedullo, W.R. Auger; UC San Diego - San Diego, CA/US

Related Stories

Adempas approved to treat pulmonary hypertension

October 9, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Protein molecule may improve survival in deadly lung disease

May 6, 2014

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to ...

Macitentan cuts morbidity, death in pulmonary arterial HTN

August 29, 2013

(HealthDay)—For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. ...

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...

Food-poisoning bacteria may be behind Crohn's disease

October 19, 2016

People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study led by researchers at McMaster University.

Neurodevelopmental model of Zika may provide rapid answers

October 19, 2016

A newly published study from researchers working in collaboration with the Regenerative Bioscience Center at the University of Georgia demonstrates fetal death and brain damage in early chick embryos similar to microcephaly—a ...

Scientists uncover new facets of Zika-related birth defects

October 17, 2016

In a study that could one day help eliminate the tragic birth defects caused by Zika virus, scientists from the Florida campus of The Scripps Research Institute (TSRI) have elucidated how the virus attacks the brains of newborns, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.